Enveda adds millions to Series C haul
Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently added $20 million to its Series C round, bringing the fundraising effort’s total to $150 million.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enveda Biosciences was recently cleared to begin clinical trials of its drug candidate for the…
-
BOULDER — Enveda Biosciences, a biotechnology company also known as Enveda Therapeutics Inc. that uses…
-
Enveda Biosciences, a biotech company focused on AI-driven drug discovery, has appointed Christopher Porter as…
-
Enveda Biosciences, a biotechnology company also known as Enveda Therapeutics Inc. that uses artificial intelligence…
